In vitro screening platform for bioactives and botanicals targeting circadian biology

Overview

This offering provides a specialized in vitro screening platform designed to evaluate dietary bioactives, nutraceutical ingredients, and complex botanical extracts for their effects on sleep quality and circadian rhythm regulation. Built on HypoE22 hypothalamic neuronal cells, an established model with direct relevance to the neurobiological mechanisms governing sleep-wake behavior, the platform enables ingredient developers to generate mechanistic evidence early in product development. It supports science-based consumer health solutions targeting sleep, relaxation, and circadian alignment.

Technical specifications

Key features:

• HypoE22 hypothalamic neuronal cell model retaining key hypothalamic characteristics relevant to circadian and sleep biology
• 96- and 384-well assay formats supporting scalable ingredient prioritization and dose-response studies
• Quantification of core circadian clock gene expression (BMAL1, CLOCK, PER1/2, CRY1/2) by RT-qPCR
• Benchmarking against melatonin-treated controls to contextualize circadian-active responses
• Evaluation of melatonin-responsive signaling pathways and neuronal activation markers (c-Fos, pCREB)
• Measurement of sleep-related neurochemical mediators and neuropeptide networks
• Sample qualification workflow including solubility assessment and cytotoxicity testing to define non-toxic concentration ranges
• Structured 8-week workflow from sample preparation through candidate ranking and final reporting
• Generation of circadian activity profiles and lead candidate selection supported by statistical analysis and quality-controlled data normalization

Technology readiness level

The platform is operational and available for contract screening engagements, with validated assays for circadian gene expression, pathway activation, and neurochemical biomarker measurement. The structured 8-week validation workflow has been defined to move test ingredients from primary circadian screening through mechanistic characterization to final candidate ranking. This positions the platform at a stage suitable for early-stage screening, lead ingredient selection, and mechanistic validation for companies developing sleep-supporting and circadian-targeted consumer health products.